GPP
AUPH icon

Great Point Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Great Point Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000,000
Closed -$20.3M – 38
2019
Q4 		$20.3M Buy
+1,000,000
New +$9.21M 1.76% 18

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Great Point Partners's AUPH Position: Q1 2021 in Review

Great Point Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2021, closing a stake of 175,000 shares — an estimated $2.42M sold.

Great Point Partners first reported a position in AUPH in Q3 2014 and held it in 11 quarters. The position peaked at $36.6M in Q3 2020. 170 funds tracked by Wall St. Rank hold AUPH as of Q1 2021.

  • Great Point Partners reported no remaining Aurinia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Great Point Partners sold 175,000 Aurinia Pharmaceuticals shares in Q1 2021, an estimated $2.42M.
  • Great Point Partners first reported a position in Aurinia Pharmaceuticals in Q3 2014 and held it in 11 quarters.
  • Great Point Partners's Aurinia Pharmaceuticals position peaked at $36.6M in Q3 2020.
  • 170 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2021.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.